Lee IC(1), Bae JS(2). Author information:
(1)Department of Cosmetic Science and Technology, Seowon University, Cheongju
28674, Republic of Korea.
(2)College of Pharmacy, CMRI, Research Institute of Pharmaceutical Sciences,
BK21 Plus KNU Multi-Omics Based Creative Drug Research Team, Kyungpook National
University, Daegu 41566, Republic of Korea.
Aloin is the major anthraquinone glycoside obtained from the Aloe species. Transforming growth factor β-induced protein (TGFBIp) is an extracellular matrix protein and released by primary human umbilical vein endothelial cells (HUVECs) and functions as a mediator of experimental sepsis. We hypothesized that aloin could reduce TGFBIp-mediated severe inflammatory responses in HUVECs and mice. Aloin effectively inhibited lipopolysaccharide (LPS)-induced release of TGFBIp and suppressed TGFBIp-mediated septic responses. Aloin suppressed TGFBIp-induced sepsis lethality and pulmonary injury. Therefore, aloin is a potential therapeutic agent for various severe vascular inflammatory diseases, with inhibition of the TGFBIp signaling pathway as the mechanism of action. [Formula: see text].
Having over 250 Research scholars worldwide and more than 400 articles online with open access.